Cancer cell 'degraders' target two proteins at once to defeat treatment resistance

AI Summary

Researchers from Technion have developed a new cancer treatment compound targeting two proteins simultaneously to overcome treatment resistance. Early tests show the compound’s effectiveness against aggressive tumor cells, representing a promising advancement in cancer therapy.

Researchers from two Technion faculties have jointly developed a new compound and demonstrated its effectiveness against aggressive tumor cells.